Summit Therapeutics Share Discussion Threads

[chrisatrdg] 27/6/2018 10:39

HM I am expecting a rise of £2.50 to £3.00 minimum on next news.The only problem is that if DMD 48 wks results are positive then that leaves next phase 3 funding which would be enormous & would need partnering.It makes sense that phase 3 is partnered by Sarepta who have deep pockets & the share price would then leap up.PR is not required if future news is supported by good science.

[abergele] 27/6/2018 10:21

HM,
I am looking,or hoping for a rise to £2.40p as per chart, with next news..
fingers X'd

[hugus maximus] 27/6/2018 10:09

I continue to be gravely concerned that Summit has no presence in any current market conversations about DMD ... anywhere!

Although we are close to a potential re-rate if 48 wk results are a success, my knowledge of Summit is more science than market based.

Does anyone with a little more experience of market scenarios at such critical junctures, have a view as to whether it matters not a jot, that NASDAQ analysts and bulletin boards currently show little interest in Summit's DMD drug?

Given the ridiculously pumped SRPT market cap, my personal guess would be that in reaction to a potentially positive EZD 48 wk RNS, the market won't have a clue and simply be confused by anything that Summit release.

Please could someone comment as to whether Summit's current PR plays any importance in the overall scheme of things? SRPT's ridiculous SP, suggests that's ALL that's important in the USA?

[hugus maximus] 27/6/2018 09:52

Someone questioning the ridiculous scenario that the DMD field has presented in the current share price at Sarepta and others ... the difference between 'us' and 'them' does seem ludicrous :

[wildbunch] 26/6/2018 22:44

HugusMax-You are so right about the PR machine. Unless we get a v good re-rating Sarepta will pick Summit off cheaply. Sarepta will know the value of Summit even if the punters do not.

[football] 25/6/2018 21:03

12.87 USD +0.52 (4.21%)

[luminoso] 25/6/2018 11:22

I would not be surprised if there was a concerted campaign to talk down the price of SMMT wherever possible on the nasdaq boards in order to give sarepta a better buying price. IMO

[hugus maximus] 24/6/2018 10:13

Sunny Sunday morning perusing various NASDAQ BB's ... Summary:

This week SRPT Gene Therapy has definitely blown open an interest for DMD therapies. Most new investors do not have a clue about the science and simply see a couple of buses coming down the road at the same time :-

One is a top of the range, shiny looking luxury vehicle that has a lick of new paint and is coming along, lead by a huge American marching band worth $10 billion ... the other, a tatty looking thing that had a couple of people buying tickets mid week, but by Friday had lost any advance bookings, worth just $200 million!

Typical quotes from folk dipping a toe in on SMMT pages :-

"they seem to be tanking lol .. so was ph2 successful? What the heck are they presenting at conferences?!!"

"there like 2 or 3 of these DMDComong up in a week"

Following a jpeg that someone cut and paste of extracts of RNS @ 24 wk EZD in January: "does this look like success lol?"

If 48 wk results are good, though it pains me to suggest, we will need make sure that there's a PR machine communicating what those facts mean in the USA. i.e. If data is good enough for potential FDA approval ... that needs broadcasting loud and clear. I have noticed Summit fans on the NASDAQ who do have a good grip of the science, have this week been ranting about lack of clarity. (Edit 25/06)

[wildbunch] 23/6/2018 12:59

I am not sure there is currently much in Summit's price for it's antibiotic programs-potential revenues are a long way down the road. So, @300m is not that far away from where we are now. I would expect a significant re-rate IF 3Q results are v good and an announcement made that accelerated approval is to be sought. It does not matter what the average Joe punter in the US thinks-what does matter is what the strategic thinker(s) in Sarepta thinks. IMHO they will be concerned that Luminoso's analysis above might be right and take us out. But-hopefully after the 3Q re-rating!

[waterloo01] 23/6/2018 09:23

Hugus, maybe but $300m with some milestones and ongoing royalties would be an excellent deal and leave them both cash rich (special divi?) and a pure play antibiotic company.

Not a bad place to be IF that's the way it plays out.

[hugus maximus] 23/6/2018 09:12

What concerns me luminoso is simply that the average Joe (NASDAQ investor) believes that after SRPT announcement re: Gene Therapy, EZD is now a waste of time. Whereas nothing could be further from the truth. None of this would matter were it not for the fact that post a successful EZD 48 wk result, SRPT may make a cheap approach and be perceived by some folk as the only game in town.

I hope that Summit resist such a move and continue on alone, rather than take something around a $300 million offer. Perhaps Lansdowne would also prefer that option?

This past week has been significant in so many contrasting ways.

[luminoso] 22/6/2018 23:10

The valuation of these DMD companies is a bit strange. A company that has a drug that barely, if at all, improves the lives of 13 percent of sufferers and a potential treatment that may help 60 percent of sufferers some way down the road, is worth fifty times more than the company which has a drug that will probably help 100 percent of sufferers live a longer more fulfilling life. And quite soon. Go figure.

[hugus maximus] 22/6/2018 10:10

Agree phowdo.

[phowdo] 22/6/2018 09:49

If it breaks $14 over the pond on decent volume then could see a good rally.
Doubt a rerating comes from London side.

[hugus maximus] 22/6/2018 09:21

SRPT Gene Therapy news has brought many NASDAQ investors to the DMD drug market, and as a consequence SMMT is seeing many more users turning up on message boards there.

I suspect on finding SMMT, many see .. a small UK company with Mrkt Cap $200 million that might be about to share the crumbs off the table of SRPT... a USA company with Mrkt Cap peaking this week at $10 Billion.

IMO This might induce a solid share price rise here toward 48 wks RNS?

[chrisatrdg] 21/6/2018 13:16

Sarepta Therapeutics: Chasing The Good News

[chrisatrdg] 21/6/2018 12:26

Summit Therapeutics
The JMP Securities Life Science Conference
New York, NY
June 21, 2018 9:30 a.m. (ET)



Happy listening at 2.30 UK Time.

Edit:

'Who knows what the future may bring' Glyn's comment in relation to Summits future relationship with Serepta.

Opening line?

[hugus maximus] 21/6/2018 10:10

football .. I heard mention at the AGM that Summit have a deposit on a whole Island ... Real Estate guys have a sign outside saying "purchase - pending"

[hugus maximus] 21/6/2018 10:03

Something occurred to me this morning after a week of all things Sarepta. Summit is not beholden to doing a deal exclusively with Sarepta. They only have an agreement with $500 million pipeline / 45% cost share etc in lieu of Europe license. I had a chat with Summit on the phone after 24 wk result and there is nothing to stop another party taking USA rights and Sarepta still have to fulfil their agreement!

BTW - thanks Freedosh .. wonderful to have a professional eye look at the Sarepta GT slide presentation.

[football] 21/6/2018 09:57

Richard Pye on holiday do we know if he's booked two weeks at Butlins or a private villa in Maldives as it might have something to do with the results after testing

[gclark] 21/6/2018 09:19

When are we expecting the 48 week topline data for the Phaseout DMD/Phase II study?